Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
M1 Kliniken AGMKLNF 92 Debt-to-EBITDA is 0.18 as of Dec. 2025, which is 65% below its 10-year median of 0.51. GuruFocus rates MKLNF with a GF Score™ of 92/100 and a GF Value™ of $10.90. Among 90 Medical Distribution companies, M1 Kliniken AG ranks better than 90% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for M1 Kliniken AG's Debt-to-EBITDA or its related term are showing as below:
MKLNF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0.51 Max: 0.86
Current: 0.18
During the past 12 years, the highest Debt-to-EBITDA Ratio of M1 Kliniken AG was 0.86. The lowest was 0.00. And the median was 0.51.
MKLNF's Debt-to-EBITDA is ranked better than 90% of 90
companies
in the Medical Distribution industry
Industry Median: 2.45
vs MKLNF: 0.18
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
M1 Kliniken AG Debt-to-EBITDA Related Terms
M1 Kliniken AG Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for M1 Kliniken AG's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, M1 Kliniken AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
M1 Kliniken AG Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, M1 Kliniken AG's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where M1 Kliniken AG's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
M1 Kliniken AG (MKLNF) has a Debt-to-EBITDA of 0.18 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on M1 Kliniken AG. This is 65% below median its historical median of 0.51. According to the industry distribution chart, M1 Kliniken AG ranks #9 out of 90 companies in the Medical Distribution industry, placing it in the top 10%.
Is M1 Kliniken AG's Debt-to-EBITDA too high?
M1 Kliniken AG's current Debt-to-EBITDA of 0.18 is 65% below median its 10-year median of 0.51. The Medical Distribution industry median Debt-to-EBITDA is 2.45. M1 Kliniken AG's value of 0.18 is 92.7% below this industry median. Based on the distribution chart, M1 Kliniken AG ranks #9 out of 90 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, M1 Kliniken AG has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does M1 Kliniken AG's Debt-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, M1 Kliniken AG ranks #9 out of 90 companies for Debt-to-EBITDA. This places M1 Kliniken AG in the top 10% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.45. M1 Kliniken AG's value of 0.18 is 92.7% below this benchmark. While the company's 10-year median is 0.51 vs. the industry median of 2.45, M1 Kliniken AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.45, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. M1 Kliniken AG's current Debt-to-EBITDA of 0.18 is 92.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on M1 Kliniken AG. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. M1 Kliniken AG's current Debt-to-EBITDA is 0.18, which is 65% below median its own 10-year median of 0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is M1 Kliniken AG stock overvalued right now?
M1 Kliniken AG (MKLNF) has a current Debt-to-EBITDA of 0.18. The stock's GF Value™ is $10.90, compared to a current price of $11.73 — trading 7.6% above its estimated fair value. The current Debt-to-EBITDA is 0.18, which is 65% below median its 10-year median of 0.51 and 92.7% below the Medical Distribution industry median of 2.45. M1 Kliniken AG's overall GF Score™ is 92/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For M1 Kliniken AG (MKLNF), the current Debt-to-EBITDA is 0.18 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is M1 Kliniken AG (MKLNF) Overvalued in 2026?
Based on GuruFocus' analysis, M1 Kliniken AG stock appears to be overvalued.
The current stock price of $11.73 is trading 7.6% above its estimated GF Value™ of $10.90.
Key valuation signals for MKLNF:
Debt-to-EBITDA: 0.18 (65% below median its 10-year median of 0.51)
GF Value™: $10.90 vs. price of $11.73 (7.6% above fair value)
Industry Position: 92.7% below the Medical Distribution median (#9 of 90)
No single metric tells the full story. See the MKLNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
M1 Kliniken AG operates in the growing market of aesthetic medicine and plastic surgery and provides aesthetic medical treatments in the self-pay segment. It operates through Beauty and Trade segments. Its activities are focused on providing aesthetic medical treatment. In addition to medical aesthetic treatments, the company also develops and markets pharmaceutical, medical, and medical technology products for aesthetic surgery and cosmetic dermatology. Some of the treatments offered by the group are lip under injection, eyebrow lift, tummy tuck, breast reduction, sweat treatment, liposuction, and others. The organization conducts its business operations in Germany. The majority of its revenue is derived from the Trade segment.
92GF Score
Get the complete analysis for MKLNF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MKLNF has been successfully added to your 
